Core Viewpoint - The collaboration between BD and Ypsomed aims to enhance self-injection systems for large-volume biologics, improving options for pharmaceutical companies and patients [1][3]. Group 1: Product Development - BD and Ypsomed are developing a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe, which will be compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform [1][2]. - The new syringe features advanced technologies such as an 8-millimeter needle and thinner wall cannulas, designed to support the delivery of higher volume and viscosity medicines [2][4]. - The syringe aims to maximize flow efficiency and reduce injection time, addressing challenges associated with large-volume biologics [4][5]. Group 2: Market Demand and Applications - There is a growing demand for patient-friendly solutions in the high-dose biologics space, particularly in oncology, autoimmune diseases, rare diseases, and metabolic disorders [3][5]. - Ypsomed's YpsoMate® 5.5, introduced in 2022, was developed to meet the needs of patients requiring large-volume subcutaneous injections, featuring an ergonomic design and intuitive activation [3][5]. Group 3: Strategic Collaboration - BD and Ypsomed have a history of collaboration, previously developing the 2.25 mL version of the Neopak™ XtraFlow™ Syringe and YpsoMate® 2.25 autoinjector, which demonstrated improved flow and optimized injection times [5]. - The partnership is focused on expanding the subcutaneous delivery design space to accommodate high-dose therapies, enhancing the development of combination products and reducing time-to-market for pharmaceutical companies [5][6]. Group 4: Future Outlook - The BD Neopak™ XtraFlow™ 5.5 mL Glass Prefillable Syringe is currently in development and will undergo comprehensive testing for compatibility with the YpsoMate® 5.5 platform, with samples expected for feasibility studies in mid-2026 [6].

Core Insights - Sisram Medical Ltd has entered into a memorandum of understanding with Sinmait Medical Technology to enhance localization efforts in China, which is expected to accelerate its strategic implementation and business expansion in the Chinese market [1][2]. Group 1: Partnership and Localization - The partnership with Fosun Pharma will allow Sisram to leverage advanced production capabilities and local expertise to establish a manufacturing hub in China, initially focusing on Energy-Based Devices (EBD) [3]. - The new facility will cater to domestic demand and serve as a strategic center for the APAC region, addressing the growing need for scalable production and advanced research and development [4]. Group 2: Strategic Vision and Market Position - The collaboration elevates Sisram's localization strategy in China, aiming to build a comprehensive and competitive localized ecosystem, which is a key milestone in the company's vision of "In China, for Global" [5]. - The synergistic development and localized manufacturing of EBD alongside other product offerings will enhance the portfolio's effectiveness, providing Chinese consumers with superior and accessible domestic wellness solutions [5]. Group 3: Company Overview - Sisram Medical Ltd is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD), serving customers in over 110 countries and regions [6]. - The company has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017 and is majority-owned by Fosun Pharma [6].

Market Overview - The market in 2025 was characterized by extreme volatility, with small caps experiencing a significant rally followed by a sharp retreat due to various uncertainties, including government policy and AI-related concerns [4][5] - Small caps outperformed large caps in earnings growth for the first time in over a decade during the third quarter, indicating an improving earnings backdrop for this asset class [5][6] - Despite challenges, the U.S. economy showed solid growth, allowing the Federal Reserve to continue its rate-cutting cycle [4] Performance Overview - The ClearBridge Small Cap Growth Strategy underperformed the Russell 2000 Growth Index in the fourth quarter, primarily due to disappointing earnings in the IT sector and a strong rally in biotechnology stocks [6][7] - The biotechnology sector saw a significant rebound, with the Russell 2000 Growth Biotech Index returning 28.1%, highlighting the challenges faced by other sectors [6] - The health care sector contributed positively to performance, with notable individual performers like Penumbra and Insmed [8][19] Portfolio Positioning - In 2025, the company established 29 new investments and exited 19 positions, indicating an active year for idea generation [10][11] - New investments included Protagonist Therapeutics, Simpson Manufacturing Company, BETA Technologies, and Dyne Therapeutics, each with strong growth potential in their respective fields [11][22] - The company maintained a disciplined approach to selling positions where fundamentals changed or catalysts were lacking [10] Outlook - The outlook for small cap growth stocks in 2026 is optimistic, with expectations for a broadening of growth leadership across various industries [13][14] - The productivity benefits of AI are anticipated to become more visible, potentially benefiting companies leveraging AI for efficiency and new product offerings [14] - Capital markets are showing signs of improvement, with increased IPO activity and M&A volumes, creating a favorable environment for small cap investments [15][16]

摘要 ： 基于国家药品监督管理局（NMPA）官网公开信息，仪器信息网对 2025 年度获得医疗器械注册证的质谱相关产品进行了盘点，并结合近六年获批数据， 试图剖析中国临床质谱产业正在发生的变化。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在此前的盘点中，仪器信息网已对2 0 2 5年度质谱新品进行了系统梳理 （点击查看： 质谱仪该以什么形态服务产业？这3 5款新品给出答案 ） 。本篇将进一步聚焦临床应用端，基于国家药品监督管理局（NMPA）官网公开信息，对2 0 2 5年度获得医疗器械注册证的质谱仪器、质谱相关 试剂盒及校准品进行全面盘点，并结合近六年获批数据，试图剖析中国临床质谱产业正在发生的变化。 六年回溯，格局变化显著 回顾2 0 2 0 - 2 0 2 5年中国市场新增获批的临床质谱仪器 （注：数据统计截止 2 0 2 5 年 1 2 月 3 1 日） ，清晰的展现出一个现象：国产质谱医疗器械的 合规化进程，已经完成了从"起步"到"放量"的阶段。 自2 0 2 0年起，国产质谱医疗器械注册证获批数量持续增长，并在2 0 2 3 ...

Core Insights - Senzime AB has secured a strategic contract with a leading Ivy League university hospital system in the US [1] - The initial phase of the contract involves the installation of 60 next-generation TetraGraph systems [1] - Full implementation is expected to result in the usage of over 10,000 disposable sensors annually from these monitors [1]

Core Viewpoint - Anteris Technologies Global Corp. announced a significant capital raise, leading to a 52.17% increase in share price during after-hours trading, reaching $8.75, following a regular session close of $5.75, which was up 12.52% [1]. Group 1: Capital Raise Details - The company plans to conduct a $200 million underwritten public offering of common stock, with underwriters having a 30-day option to purchase an additional $30 million in shares at the offering price [2]. - Anteris has also agreed to sell up to $90 million in common stock to Medtronic plc through a private placement, with Medtronic set to acquire between 16% and 19.99% of shares outstanding after the public offering [3]. Group 2: Use of Proceeds - Proceeds from the capital raise will be utilized to support the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe aortic stenosis, as well as to expand manufacturing capacity and development for v2vmedtech, inc. [5]. Group 3: Trading Metrics and Analysis - Anteris has a market capitalization of $236.89 million, with its stock trading within a 52-week range of $2.34 to $8.79. Over the past 12 months, the stock has seen a decline of 2.21%, indicating ongoing challenges for the company [6]. - The stock is currently positioned at 52.9% of its 52-week range, nearing yearly highs, and has a Relative Strength Index (RSI) of 66.01, suggesting a positive price trend across all time frames [6][7].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million before expenses [1][2]. Group 1: Offering Details - The public offering consists entirely of shares sold by the Company, with underwriters granted a 30-day option to purchase an additional 5,217,391 shares [2]. - The Offering is expected to close on January 22, 2026, pending customary closing conditions [1]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, contingent on the completion of the public offering [3]. - The private placement will require a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the Offering and the Private Placement will support the growth and clinical strategy of the Company, including the DurAVR Transcatheter Heart Valve global pivotal trial [4]. - Funds will also be allocated to expand manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining proceeds for working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is focused on developing innovative medical devices for heart function restoration, with a significant presence in both Australia and the USA [10]. - The lead product, DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [11].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].

Summary of Conference Call Notes Industry Overview - The medical devices industry in China is expected to face ongoing pricing pressures in 2026, particularly for in vitro diagnostics (IVD) players, although some recovery in medical equipment sales is anticipated. Niche consumable segments may benefit from value-based pricing (VBP) and globalization trends [1][2][3]. Company-Specific Insights Imeik Technology Development Co Ltd (300896.SZ) - **Rating Downgrade**: Imeik has been downgraded from Equal-weight (EW) to Underweight (UW) with a price target (PT) maintained at Rmb130. The downgrade is attributed to intensifying competition, soft domestic demand, and weakening bargaining power, leading to persistent pricing and margin pressures on its core products, Hearty and CureWhite [3][4][32]. - **Sales Forecast**: A projected 20% year-over-year (YoY) sales decline for 2025 is expected, with 4Q results likely flat quarter-over-quarter (QoQ) due to higher selling, general, and administrative expenses (SG&A). A recovery to high single-digit growth is anticipated in 2026, supported by stable legacy products and contributions from new products like Hutox [3][33][34]. - **Valuation Concerns**: The stock is trading at approximately 29 times the estimated earnings per share (EPS) for 2026, which is considered full given the low-teens growth outlook and limited visibility due to macroeconomic and competitive challenges [3][34][37]. Mindray Bio-Medical Electronics Co Ltd (300760.SZ) - **Revenue Decline**: Expected to post a 9% YoY revenue decline for 2025, with a modest recovery anticipated in 2026. The net profit is also projected to decline by double digits in 2025 [8][10]. United Imaging Healthcare Co (688271.SS) - **Sales Growth**: Anticipated to achieve over 20% sales growth in 2025, with net profit growth expected to exceed 40-50% due to a low profit base in 2024 [8][10]. APT Medical Inc (688617.SS) - **Growth Projections**: Expected to see approximately 24% overall sales growth and 28% net profit growth in 2025, with strong performance in 4Q [11][19]. Zylox-Tonbridge Medical Technology Co (2190.HK) - **Market Position**: Likely to benefit from VBP tailwinds in neuro and peripheral intervention devices, with potential upside surprises in sales growth [12][19]. Peijia Medical Ltd (9996.HK) - **Revenue Expectations**: Projected TAVR revenue for 2025 is estimated to be below Rmb300 million due to a voluntary product shipment delay [13][19]. Angelalign Technology Inc (6699.HK) - **Performance Outlook**: Expected to outperform targets due to resilient growth in China and lower costs [8][19]. Key Trends and Risks - **Market Dynamics**: The medical device tender value rebounded by 30.1% YoY in 2025, approaching 2022 levels, indicating a recovery in various categories despite challenges in IVD analyzers [25][26]. - **Competitive Landscape**: Increasing competition in the dermal filler market is noted, with Imeik facing challenges from new product launches and changing market dynamics [32][37]. - **Regulatory Environment**: Updates on VBP implementation and pricing strategies are critical for future performance, particularly for companies like Imeik and Peijia [15][34]. Conclusion The medical devices industry in China is navigating a complex landscape characterized by pricing pressures, competitive challenges, and varying growth prospects across companies. Imeik Technology's downgrade reflects broader concerns about market dynamics and profitability, while other companies like United Imaging and APT Medical show potential for growth amidst these challenges.

Market Overview - A-shares experienced a rebound with the ChiNext index rising over 1%, while gold stocks continued to strengthen. Storage chips and GPU concepts saw an increase, whereas the AI application sector continued to adjust [1] - The Hang Seng Index showed mixed performance, initially declining before recovering, with tech stocks displaying divergence and sectors like semiconductors and chemicals rising [2][3] - The bond market saw most government bond futures decline, with the 30-year contract up by 0.28% and the 10-year contract down by 0.02% [3][4] Commodity Market - Domestic commodity futures exhibited mixed results, with lithium carbonate surging over 5% and焦煤 (coking coal) dropping over 3%. Other commodities like platinum and palladium also saw gains [4][5] - Gold prices reached a historic high, surpassing $4800 per ounce, while silver also saw significant gains, up 33% year-to-date [7][17] Sector Performance - The GPU sector saw a notable surge, with stocks like 龙芯中科 (Loongson Technology) hitting the daily limit and 海光信息 (Haiguang Information) rising over 13% [8][9] - The medical device sector was active, with stocks like 天智航 (Tianzhihang) rising over 10% following the announcement of new pricing guidelines for medical services [15][17] - The storage chip sector continued its strong performance, with stocks like 盈方微 (Yingfang Micro) achieving consecutive gains [13] Key Stock Movements - In the gold sector, 湖南白银 (Hunan Silver) saw a significant increase of 9.35%, while other gold-related stocks also experienced gains [6] - The ChiNext 50 index expanded its gains to 3.4%, reflecting strong investor interest in technology and innovation sectors [10] - The Hang Seng Index and Hang Seng Tech Index showed slight increases of 0.07% and 0.28%, respectively, indicating a stable market environment [2][3]